OB) is pleased to announce that it is common shares have been approved for listing on the NASDAQ Capital Market. Aradigm expects its shares to begin with trading on NASDAQ on Wednesday, June 11, 2014 http://cialisdanmark.net cialisdanmark.net . The Company will trade beneath the ticker symbol ARDM. The move to NASDAQ is a significant milestone for Aradigm and underscores our dedication to grow the value of our Firm and broaden our shareholder base, said Igor Gonda, CEO and President of Aradigm Company. We believe it will provide more liquidity for our shareholders. The solid fundamentals of the business together with the increased visibility that NASDAQ will provide should help us in maximizing shareholder value over the short and long term.
Arcturus Therapeutics was founded by Joseph Pad and Payne Chivukula, pharmaceutical scientists and experts in nanoparticle delivery technology and who have previously executed a preclinical development project through IND submitting for a novel RNAi therapeutic to take care of fibrosis. The Arcturus founders possess considerable experience delivering multiple drug products for reputable companies, such as DuPont Pharmaceuticals, Merck, Bristol-Myers Squibb, Kalypsys and Nitto Denko. Recently, Arcturus announced new appointments to its Panel of Scientific and Directors Advisory Board.. Arcturus Therapeutics closes $1.3 M in seed funding round Arcturus Therapeutics, Inc., an industry leader in RNAi technologies for the treating disease, today announced it provides elevated $1.3 million in a seed funding round led by multiple high net-worth private investors from america and Canada.